We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Every step we have taken as part of our approach to COVID-19 testing has been a careful balancing of risks and benefits in order to meet the urgent public health needs as we combat this new pathogen.
Biomerica has signed two separate definitive license agreements with Mount Sinai’s Icahn School of Medicine in New York to license technologies pertaining to a laboratory version serological test ...